Bridging the Gap between Product Readiness and Equipment Availability
2025-12-15 11:00 - 12:00 (America/New_York)
Launch-ready & peak-proof: Discover how to bridge packaging gaps and act as a reliable backup during demand surges. You’ll learn how manual precision at an industrial scale ensures seamless transitions to automated packaging, and why this approach is a game-changer for accelerating product launches.

Overcoming Regulatory Hurdles in AAV Production
2025-12-16 11:00 - 12:00 (America/Los_Angeles)
As cell and gene therapy (CGT) advances, regulatory expectations around product quality and manufacturing rigor continue to rise—especially in viral vector production. One emerging challenge is the need to demonstrate clearance of residual reagents used during upstream processing, a requirement increasingly emphasized by regulatory agencies like the FDA.
In this webinar, Miguel Dominguez and Lloyd Achirem from Mirus Bio (part of MilliporeSigma) will explore how AAV manufacturers can address this pain point through strategic partnerships and innovations. We’ll introduce a newly developed residual reagent assay tailored to Mirus Bio solutions that helps streamline regulatory submissions and supports quality assurance in viral vector workflows.
Join us to learn how the team can support your compliance strategy and hear directly from the experts driving these innovations in AAV production.

Advancing targeted in vivo LNPs: Five practical considerations to move from concept to clinic
2025-12-17 11:00 - 12:00 (America/Los_Angeles)
As genetic medicine advances toward targeted in vivo delivery, developers face new challenges in translating promising concepts into clinical reality. From payload design to conjugation chemistry and analytics, each decision shapes manufacturability, scalability, and regulatory success.
In this webinar, experts from Cytiva will share five practical considerations for teams advancing targeted in vivo LNP programs — covering formulation selection, conjugation and targeting strategies, bioanalytical readiness, process complexity, and the approaches to enable clinical development.
Drawing on experience from ARPA-H-funded initiatives and real-world collaborations, the discussion will explore proven strategies that help innovators anticipate and overcome common development hurdles.
Attendees will walk away with a framework for designing in vivo programs that are technically robust, scalable, and ready for clinical advancement — helping teams accelerate the journey from concept to clinic.
